DataDerm in Action: AAD Launches Project to Improve Outcomes for GPP Patients

The project will connect DataDerm’s 50 million deidentified patient encounters with OM1’s AI-based Patient Finder tool to improve understanding of GPP patients’ journey, treatment patterns, disease progression, and outcomes. 

The American Academy of Dermatology is launching a new project to develop educational resources to improve the evaluation, diagnosis, and treatment of patients with generalized pustular psoriasis (GPP).

The AAD is working with Boehringer Ingelheim and using OM1’s data aggregation system and its PhenOM artificial intelligence (AI) platform for this initiative.

The AAD’s new Generalized Pustular Psoriasis Education Initiative will tap into data in the Academy’s DataDerm dermatology patient registry.  The project will connect DataDerm’s 50 million deidentified patient encounters with OM1’s AI-based Patient Finder tool to improve understanding of GPP patients’ journey, treatment patterns, disease progression, and outcomes. 

The insights gathered will help inform the development of educational resources and tools for dermatologists, referring physicians, and patients aimed at improving the quality of life for GPP patients.

“The American Academy of Dermatology is committed to excellence in dermatology and finding innovative approaches to improve patient care,” says AAD President Terrence A. Cronin Jr., MD., FAAD, in a news release.  “Though rare, GPP can cause patients incredible pain and suffering. While maintaining our focus on patient privacy, this project will break new ground and provide us with resources that will have a significant impact on these patients’ lives.”

“We are proud to support this important initiative by the American Academy of Dermatology,” adds Dr. Lennart Jungersten, U.S. Medical Director, Boehringer Ingelheim. “We believe that our joint efforts can generate more awareness and improve the quality of care for patients living with rare skin conditions including GPP.”

“OM1 is excited to support the American Academy of Dermatology’s work in expanding resources to serve GPP patients,” says Joseph Zabinski, PhD, managing director of AI & Personalized Medicine, OM1. “Artificial intelligence is a powerful tool for understanding patterns in rare disease patients’ journeys, and we look forward to using AI to study these journeys in DataDerm to improve outcomes in GPP.”

Findings from the first phase of the project will be shared at the American Academy of Dermatology’s 2024 Annual Meeting, March 8 – 12 in San Diego.